{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:23:52Z","timestamp":1787009032715,"version":"build-2736575974"},"reference-count":11,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T00:00:00Z","timestamp":1769990400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>While tigecycline has been associated with hypofibrinogenaemia, limited data with eravacycline suggest this may also occur with this agent. However, the incidence and clinical significance of this finding are not well defined.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This is a retrospective cohort study of hospitalized adults who received at least two doses of eravacycline between 1 August 2018 and 1 October 2024 and had two or more fibrinogen levels monitored while on therapy. The primary outcome was \u226550% reduction in fibrinogen while on eravacycline. Secondary outcomes included \u226525% reduction in fibrinogen, time to 50% fibrinogen reduction, development of hypofibrinogenemia (&amp;lt;200\u2005mg\/dL) and bleeding events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Thirty-nine patients were included with 17 (44%) being solid organ transplant recipients and 11 (28%) patients not considered to be immunocompromised. Eravacycline was primarily used to treat nontuberculosis mycobacterial infections (82%). The median (IQR) duration of eravacycline therapy was 12 (8\u201322) days. Thirty-three per cent of patients met the primary outcome of \u226550% decrease in fibrinogen with a median (IQR) time to 50% decrease in fibrinogen of 10 (8\u201311) days. A substantially higher number, 79%, experienced \u226525% reduction in fibrinogen. Hypofibrinogenaemia developed in 18 (49%) patients. A total of four (10%) patients experienced minor bleeding events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>A majority of eravacycline-treated patients experienced at least a 25% decrease in fibrinogen levels. Although the decreased fibrinogen levels did not result in major clinically significant bleeding, fibrinogen levels should be monitored at baseline and at least weekly. Patients should also be monitored for any signs and symptoms of bleeding.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jac\/dkag030","type":"journal-article","created":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T12:43:53Z","timestamp":1768394633000},"source":"Crossref","is-referenced-by-count":3,"title":["Impact of eravacycline on fibrinogen"],"prefix":"10.1093","volume":"81","author":[{"given":"Emily","family":"Stevenson","sequence":"first","affiliation":[{"name":"Department of Pharmacy, University of North Carolina Medical Center , Chapel Hill, NC ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madison","family":"Ponder","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina , Chapel Hill, NC ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsay","family":"Daniels","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, University of North Carolina Medical Center , Chapel Hill, NC ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Travis","family":"Jones","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, University of North Carolina Medical Center , Chapel Hill, NC ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luther","family":"Bartelt","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, University of North Carolina , Chapel Hill, NC ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4784-3227","authenticated-orcid":false,"given":"David","family":"Van Duin","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, University of North Carolina , Chapel Hill, NC ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8585-1722","authenticated-orcid":false,"given":"Brent","family":"Footer","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, University of North Carolina Medical Center , Chapel Hill, NC ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,2,6]]},"reference":[{"key":"2026020606194012800_dkag030-B1","unstructured":"Tigecycline \u00a0[package insert]. Sandoz; 2025."},{"key":"2026020606194012800_dkag030-B2","unstructured":"Eravacycline \u00a0[package insert]. Tetraphase Pharmaceuticals; 2018."},{"key":"2026020606194012800_dkag030-B3","unstructured":"Omadacycline \u00a0[package insert]. Paratek Pharmaceuticals; 2025."},{"key":"2026020606194012800_dkag030-B4","doi-asserted-by":"publisher","first-page":"ofac591","DOI":"10.1093\/ofid\/ofac591","article-title":"Eravacycline associated hypofibrinogenemia: a case series of transplant patients with Mycobacterium abscessus infections and review of literature","volume":"9","author":"Rausch","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"2026020606194012800_dkag030-B5","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1080\/1120009X.2022.2105488","article-title":"Analysis of the clinical characteristics of tigecycline-induced hypofibrinogenemia","volume":"35","author":"Lei","year":"2023","journal-title":"J Chemother"},{"key":"2026020606194012800_dkag030-B6","doi-asserted-by":"publisher","first-page":"e70213","DOI":"10.1111\/cts.70213","article-title":"Identification of risk factors and predictive indicators for tigecycline-associated hypofibrinogenemia","volume":"18","author":"Liu","year":"2025","journal-title":"Clin Transl Sci"},{"key":"2026020606194012800_dkag030-B7","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1007\/s00228-020-02860-w","article-title":"Clinical characteristics and risk factors of tigecycline-associated hypofibrinogenaemia in critically ill patients","volume":"76","author":"Hu","year":"2020","journal-title":"Eur J Clin Pharmacol"},{"key":"2026020606194012800_dkag030-B8","doi-asserted-by":"publisher","first-page":"2717","DOI":"10.1007\/s00210-024-03419-7","article-title":"Incidence, characteristics, and risk factors of hypofibrinogenemia induced by generic tigecycline: a retrospective study","volume":"398","author":"Ma","year":"2025","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"2026020606194012800_dkag030-B9","unstructured":"HEMOSIL (Q.F.A. Thrombin). Instrumentation Laboratory. Werfen."},{"key":"2026020606194012800_dkag030-B10","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.ijid.2022.08.014","article-title":"Serum concentration as a predictor of tigecycline-induced hypofibrinogenemia in critically ill patients: a retrospective cohort study","volume":"123","author":"Yang","year":"2022","journal-title":"Int J Infect Dis"},{"key":"2026020606194012800_dkag030-B11","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s44280-025-00072-4","article-title":"Comparative efficacy of eravacycline and tigecycline in addressing multidrug-resistant gram-negative bacteria","volume":"3","author":"Zhang","year":"2025","journal-title":"One Health Adv"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/81\/3\/dkag030\/66797344\/dkag030.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/81\/3\/dkag030\/66797344\/dkag030.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T11:19:48Z","timestamp":1770376788000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/doi\/10.1093\/jac\/dkag030\/8466248"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,2]]},"references-count":11,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,2,2]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkag030","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,3]]},"published":{"date-parts":[[2026,2,2]]},"article-number":"dkag030"}}